+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Peptide Drug Conjugates - Global Strategic Business Report - Product Thumbnail Image

Peptide Drug Conjugates - Global Strategic Business Report

  • Report
  • February 2026
  • 282 Pages
  • Global
From
From
Bispecific Antibodies - Global Strategic Business Report - Product Thumbnail Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • February 2026
  • 104 Pages
  • Global
From
From
Precision Oncology Market - Global Strategic Business Report - Product Thumbnail Image

Precision Oncology Market - Global Strategic Business Report

  • Report
  • February 2026
  • 382 Pages
  • Global
From
Cancer Biological Therapy - Global Strategic Business Report - Product Thumbnail Image

Cancer Biological Therapy - Global Strategic Business Report

  • Report
  • February 2026
  • 211 Pages
  • Global
From
Testicular Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Testicular Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 269 Pages
  • Global
From
Hepatocellular Carcinoma Drugs - Global Strategic Business Report - Product Thumbnail Image

Hepatocellular Carcinoma Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 198 Pages
  • Global
From
Bone Cancer Treatment - Global Strategic Business Report - Product Thumbnail Image

Bone Cancer Treatment - Global Strategic Business Report

  • Report
  • February 2026
  • 367 Pages
  • Global
From
Oncology Clinical Trials - Global Strategic Business Report - Product Thumbnail Image

Oncology Clinical Trials - Global Strategic Business Report

  • Report
  • February 2026
  • 283 Pages
  • Global
From
MEK Inhibitors - Global Strategic Business Report - Product Thumbnail Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • February 2026
  • 132 Pages
  • Global
From
Blood Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Blood Cancer Therapeutics - Global Strategic Business Report

  • Report
  • February 2026
  • 291 Pages
  • Global
From
Esophageal Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Esophageal Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 269 Pages
  • Global
From
Combination Antibody Therapy - Global Strategic Business Report - Product Thumbnail Image

Combination Antibody Therapy - Global Strategic Business Report

  • Report
  • February 2026
  • 196 Pages
  • Global
From
Gynecological Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 193 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • February 2026
  • 224 Pages
  • Global
From
Immune Checkpoint Inhibitors - Global Strategic Business Report - Product Thumbnail Image

Immune Checkpoint Inhibitors - Global Strategic Business Report

  • Report
  • February 2026
  • 194 Pages
  • Global
From
Urothelial Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Urothelial Cancer Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 126 Pages
  • Global
From
Sarcoma Drugs - Global Strategic Business Report - Product Thumbnail Image

Sarcoma Drugs - Global Strategic Business Report

  • Report
  • February 2026
  • 126 Pages
  • Global
From
Cancer Immunotherapy - Global Strategic Business Report - Product Thumbnail Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • February 2026
  • 291 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more